Private Market View

China Boron Neutron

Hangzhou, China · Founded 2023 · Privately Held (backing)

PA Mark · $/share
$0
Sep 2026
Implied valuation
Total raised
$13.9M
Last round

Key facts

as of Sep 2026
  • It has raised $13.9M; the latest was Early Stage VC in Aug 2025.
  • Notable investors include CAS Star, Zhejiang Caitong Capital Investment, Hangzhou Huadian Investment Management, Huzhou Industrial Group, Kaitai Capital8 tracked in total.
  • 1 institutional filer reports fund marks on China Boron Neutron across 19 filings.
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$0per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 1 inputs:N-PORT marks 100%
Free account
See the evidence behind this price
  • ·The complete investor list — 8 names
  • ·Watchlist + deal alerts for China Boron Neutron
  • ·The full record, as it builds
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in China Boron Neutron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

1 filers · latest Mar 2026

1 SEC-registered fund reported 19 fair-value marks on China Boron Neutron between Dec 2025 and Mar 2026. Filer-level marks and implied $/share are available to Pro members.

Funding rounds

No rounds on record

No funding rounds for China Boron Neutron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About China Boron Neutron

Manufacturer of boron neutron capture therapy devices aims to advance innovative cancer diagnosis and treatment. The company's offerings feature medical accelerator-based neutron sources, boron-containing targeted drugs, and diagnostic-therapeutic software platforms, supported by complete industrialization workflows and independent intellectual property rights, enabling the clinical application and commercialization of advanced BNCT for late-stage malignant tumors.

Sector
Healthcare
HQ
Hangzhou, China
Founded
2023
Ownership
Privately Held (backing)